Discover pharmaceutical sciences最新文献

筛选

英文中文

Concomitant activation of D₁ dopamine and α_2A adrenergic receptors improves cognition better than methylphenidate in two rodent behavioral tests. 在两项啮齿动物行为测试中，同时激活D1多巴胺和α2A肾上腺素能受体比哌醋甲酯更能改善认知。

Discover pharmaceutical sciences Pub Date : 2026-01-01 Epub Date: 2026-06-18 DOI: 10.1007/s44395-026-00047-3

Luke Bransom, Ava P Bassett, Mi Zhou, Richard B Mailman, Yang Yang

{"title":"Concomitant activation of D1 dopamine and α2A adrenergic receptors improves cognition better than methylphenidate in two rodent behavioral tests.","authors":"Luke Bransom, Ava P Bassett, Mi Zhou, Richard B Mailman, Yang Yang","doi":"10.1007/s44395-026-00047-3","DOIUrl":"10.1007/s44395-026-00047-3","url":null,"abstract":"Rationale: Methylphenidate is commonly prescribed to manage symptoms of attention-deficit/hyperactivity disorder (ADHD), but like other stimulants it has variable effectiveness. Methylphenidate works by increasing the synaptic availability of dopamine and norepinephrine, resulting in stimulation of dopaminergic and adrenergic receptors. One hypothesis is that selective receptor targeting may be more effective clinically and have fewer side effects than non-selective stimulants.Objectives and methods: To test this hypothesis, we compared methylphenidate with three compounds: the selective D1/5 dopamine agonist 2-methyldihydrexidine; the selective α2A adrenergic agonist guanfacine; and the cannabinoid compound cannabigerol, that has α2A agonist properties and was included given the increasing recreational cannabis use among individuals with ADHD. Acute effects on temporal order memory, cognitive flexibility, and spatial working memory were evaluated using two rodent behavioral tasks.Results: Co-administration of an α2A agonist and a D1 agonist produced greater cognitive improvement than methylphenidate, but only in rats with poor baseline performance.Conclusions: These findings suggest that potential benefits may emerge from the coadministration of selective agents (e.g., α2A and D1 agonists) and should be considered for further study, especially regarding individuals with decrements in cognitive function.","PeriodicalId":524118,"journal":{"name":"Discover pharmaceutical sciences","volume":"2 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13326939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148379542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0